Bispecific t cell engagers
Bispecific T cell engagers targeting DLL3, MUC17, and CLDN18.2 activate T-cells to specifically kill cancer cells, addressing the limitations of conventional therapies by enhancing treatment efficacy with reduced side effects.
US20260055206A1Pending Publication Date: 2026-02-26SUZHOU ZELGEN BIOPHARML
0 Cites 0 Cited by
Patent Information
- Application Number
- US19/369942
- Authority / Receiving Office
- US · United States
- Patent Type
- Applications(United States)
- Current Assignee / Owner
- Priority Date
- 2020-03-17
- Filing Date
- 2025-10-27
- Publication Date
- 2026-02-26
AI Technical Summary
Technical Problem
Conventional cancer treatments, such as chemotherapy and radiation therapy, often have significant side effects due to their non-specific targeting of fast-dividing cells, and there is a need for more targeted therapies with fewer adverse effects.
Method used
Development of bispecific T cell engagers that bind to cancer-specific antigens like DLL3, MUC17, and CLDN18.2, activating CD3, CD28, and CD137 to enhance T-cell cytotoxicity and target cancer cells specifically.
Benefits of technology
The bispecific molecules effectively activate T-cells to kill cancer cells, reducing side effects by targeted therapy and enhancing treatment efficacy against cancers like SCLC and neuroendocrine tumors.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided are bispecific T Cell Engagers. More specifically, the invention is directed to bispecific molecules that bind to DLL3, MUC17 or CLD18 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and / or CD137.
Need to check novelty before this filing date? Find Prior Art